ALDX
Aldeyra Therapeutics Inc
NASDAQ · Biotechnology
$5.53
+0.44 (+8.64%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 34.78M | 32.14M | 39.05M |
| Net Income | 5.77M | 7.01M | 8.10M |
| EPS | — | — | — |
| Profit Margin | 16.6% | 21.8% | 20.7% |
| Rev Growth | +3.0% | +6.5% | +17.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 21.85M | 18.55M | 22.16M |
| Total Equity | 134.79M | 127.44M | 137.28M |
| D/E Ratio | 0.16 | 0.15 | 0.16 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 11.08M | 11.55M | 13.91M |
| Free Cash Flow | 4.11M | 3.56M | 7.02M |